Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

JANX007

Bispecific antibody · Immune activation, directed at prostate-specific membrane antigen (PSMA) (FOLH1) and CD3 (T-cell receptor complex) (CD3E) · developed by Janux Therapeutics

Phase 1 Most advanced trial
JANX Developer
1 Registered trials

What is JANX007?

JANX007 is a protease-activated T-cell engager that binds PSMA on tumor cells and CD3 on T-cells, with a peptide mask and albumin-binding domain that are released when a tumor protease cleaves its linker in the tumor microenvironment. It is being studied in prostate cancer, including castration-resistant and metastatic disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
prostate-specific membrane antigen (PSMA) (FOLH1), CD3 (T-cell receptor complex) (CD3E)
Mechanism
Immune activation, directed at prostate-specific membrane antigen (PSMA) (FOLH1) and CD3 (T-cell receptor complex) (CD3E)
Pathways
T-cell mediated cytotoxicity
Therapy area
Oncology
Developer
Janux Therapeutics (JANX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07813637 Phase 1 Prostate Cancer Recruiting JANX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Castration-Resistant Prostate Cancer (CRPC)Metastatic Castration-Resistant Prostate Cancer PatientsMetastatic Prostate CancerProstate Cancer

Other drugs acting on FOLH1 / CD3E

More from Janux Therapeutics

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the JANX page.

Follow JANX, the company behind JANX007

See JANX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

JANX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.